
summari januari report sale result
consensu shi
estim report adjust ep in-lin
estimate/consensu organ growth
compar consensu estim
respect although organ growth came street
expect repres deceler vs
worth note organ growth acceler stack
basi abt med devic organ dx organ
ex-alr busi led growth help off-set slowdown
nutrit organ epd organ altogeth
post full-year organ growth excess
anoth year double-digit ep growth y/i call
guid organ sale growth vs
estim adj ep also bracket
estimate/consensu abt initi outlook in-
line modestli better expect
chang estim lower sale estim
organ part account
wind-down non-cor asset nutrit increas
adj ep estim report maintain
price target base adj
ep estim
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep continu
oper ep includ stj amo alr deal
compani data secur llc estim reuter
ep in-lin sale fall shi street expect report adjust ep
in-lin consensu estim guidanc rel model lower net
expens vs estim tax rate vs estim off-set
lower revenu gross margin opex mostli in-lin forecast total
revenu organ ex-fx acquisitions/divestitures/wind-down vs
estim miss consensu estim howev organ growth acceler
stack basi total us sale organ ou sale
organ slightli model nutrit sale miss consensu
estim organ growth slow reflect slower growth
pediatr vs slight improv adult vs
diagnost dx sale beat consensu forecast organ growth
mostli stabl ex-alr vs ex-alr despit slower poc growth vs
alr sale exceed estim medic devic sale
miss consensu estim organ growth slow modestli
epd establish pharmaceut sale consensu
forecast organ growth slow ex-fx due
primarili tough y/i comp
devic continu drive growth post strong med devic growth
organ modest declar vs growth devic growth led diabet
organ electrophysiolog ep organ structur heart organ diabet saw
robust growth behind continu adopt libr ep driven ablat strength structur
heart led mitraclip grew ex-fx global basi pocket soft
organ vascular organ abt neuromodul nmd franchis continu impact
lag hire relat compani spinal cord stimul salesforc manag said
expect nmd growth improv sequenti throughout separ heart failur growth
weak manag expect see improv come quarter
behind destin therapi dt indic heartmat said rhythm manag
franchis grow roughli in-lin broader market modestli regard vascular
attribut soft de drug elut stent market challeng price reduct
third-parti royalti revenu manag said xienc sierra well captur share
libr growth remain robust provid updat roll-out libr continu
progress ou remain pleas rapid global uptak libr ad patient
total number ww libr user roughli strong adopt translat
sale slightli estim ou libr adopt continu
robust contribut vs estim quarter addit
manag note libr product expect come market shortli timelin
still remain somewhat vagu sens could see libr approv around mid-
year believ libr would strengthen adopt product alerts/alarm
would especi attract type popul
guidanc in-lin modestli ahead expect today call provid
initi guidanc compani expect organ sale growth bracket
previou current estim regard fx manag expect report sale headwind
roughli vast major impact expect segment wise nutrit
expect grow low mid-singl digit current model organ legaci diagnost
expect grow mid high-singl digit rapid dx alr expect grow low mid-singl
digit model overal dx growth organ epd expect grow mid high-singl
digit model organ med devic expect grow high-singl digit
model organ move full-year gross margin expect somewhat
reflect underli gross margin improv partial off-set fx compar
gross margin manag expect sg spend
sale respect regard tax rate expect tax rate reflect
anticip impact tax reform bottom-lin guid adj ep
bracket consensu previou estim manag expect fx headwind
ep impli adj ep growth mid-teen underli basi
guidanc introduc guid organ sale growth littl less
manag note face tough prior year comp particularli dx due strong flu season
year ago look abt guidanc busi epd expect grow mid-singl digit includ
mid high-singl digit key emerg market em segment modest declin epd
sale due discontinu third-parti suppli agreement nutrit expect grow low mid-
singl digit abt legaci dx franchis expect grow mid high-singl digit rapid
diagnost alr expect rel flat med devic expect grow high-singl digit
manag expect fx advers impact report sale bottom-
line guid adj ep consensu like due fx
manag note adj ep guidanc reflect double-digit underli growth partial off-set fx
price target nc
price target base ep estim risk target includ
slower growth key busi market delay stj alr integr slower margin
expect continu deliv double-digit underli ep growth mid-singl digit underli
sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
 incom statement million except per good sold profit profit includ includ med-tech ex-medtech profit profit includ expens fx loss expens ep continu ep includ discontinu analysiscost good margin margin profit profit compani report secur llc estim medic technolog
